Program
insulin degludec
Also written as “insulin degludec/insulin aspart”, “insulin degludec/liraglutide” and “Insulin degludec”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 1000 open or running | phase 4since Sep 21, 2018 | Jan 30, 2008 | none ahead |
| Tonghua Dongbao Pharmaceutical | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Gan & Lee Pharmaceuticals | 11 open or running | phase 1since Aug 18, 2025 | Aug 18, 2025 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 3since Jul 5, 2021 | Jul 5, 2021 | none ahead |
| Sunshine Lake Pharma | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since May 31, 2011.
- May 3, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02762578, NCT02773368
- Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
- Sep 15, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02906917, NCT02911948
- Mar 10, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03078478 · 1,609 enrolled · United States, Canada, Denmark and more
- May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
- Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
- Nov 16, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03377699 · 225 enrolled · Argentina, Australia, Austria and more
- Sep 21, 2018Phase 4 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT03687827 · 498 enrolled · United States, Canada, Poland and more
- Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
- Jul 5, 2021Sino Biopharmaceutical's first study: phase 3 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04955834 · 344 planned · China
- Mar 6, 2023Sunshine Lake Pharma's first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
- Jun 2, 2024Tonghua Dongbao Pharmaceutical's first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
- Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
- Aug 18, 2025Gan & Lee Pharmaceuticals's first study: phase 1 study in Diabetes Mellitus, Type 2New to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT07146347 · 14 planned · Germany
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07146347Diabetes Mellitus, Type 2 · Germany | 1 | Recruiting | Gan & Lee Pharmaceuticals | Apr 1, 2026 | 14 |
| NCT06559722Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Tonghua Dongbao Pharmaceutical | Oct 2025 | 510 |
| NCT06449703Healthy · China | 1 | Recruiting | Tonghua Dongbao Pharmaceutical | Jun 16, 2024 | 44 |
| NCT05802862Diabetes Mellitus · China | 3 | Completed | Sunshine Lake Pharma | Aug 16, 2024 | 414 |
| NCT04955834Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Sino Biopharmaceutical | Dec 31, 2025 | 344 |
| NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Novo Nordisk | Jun 23, 2022 | 588 |
| NCT03687827Diabetes Mellitus, Type 2 · United States, Canada, Poland and more | 4 | Completed | Novo Nordisk | Dec 20, 2019 | 498 |
| NCT03377699Diabetes Mellitus · Argentina, Australia, Austria and more | 3 | Completed | Novo Nordisk | Dec 17, 2020 | 225 |
| NCT03292185Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Jan 2, 2018 | 24 |
| NCT03175120Diabetes Mellitus · China, Hong Kong | 3 | Completed | Novo Nordisk | Mar 5, 2019 | 453 |
| NCT03172494Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | Jun 14, 2019 | 720 |
| NCT03078478Diabetes Mellitus · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Feb 13, 2019 | 1,609 |
| NCT02911948Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 17, 2017 | 210 |
| NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more | 3 | Completed | Novo Nordisk | Aug 31, 2017 | 532 |
| NCT02844790Healthy · China | 1 | Completed | Novo Nordisk | Sep 26, 2016 | 24 |
| NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Sep 26, 2017 | 420 |
| NCT02762578Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | May 19, 2017 | 543 |
| NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more | 3 | Completed | Novo Nordisk | Sep 4, 2016 | 263 |
| NCT02607306Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Dec 15, 2017 | 819 |
| NCT02536859Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Apr 14, 2016 | 60 |
| NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Completed | Novo Nordisk | Oct 3, 2018 | 1,012 |
| NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more | 3 | Completed | Novo Nordisk | Oct 5, 2016 | 506 |
| NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Dec 23, 2015 | 420 |
| NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 2015 | 31 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02030600Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Dec 4, 2015 | 721 |
| NCT01959529Diabetes Mellitus · United States, Algeria, Argentina and more | 3 | Completed | Novo Nordisk | Oct 16, 2016 | 7,637 |
| NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Nov 4, 2014 | 557 |
| NCT01916174Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2013 | 50 |
| NCT01880736Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Apr 2014 | 458 |
| NCT01868581Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 58 |
| NCT01868568Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 55 |
| NCT01868555Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Feb 2008 | 32 |
| NCT01868529Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2008 | 63 |
| NCT01865331Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2007 | 32 |
| NCT01865318Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jan 2007 | 36 |
| NCT01865305Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2007 | 59 |
| NCT01865292Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2006 | 40 |
| NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Completed | Novo Nordisk | May 15, 2014 | 833 |
| NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more | 3 | Completed | Novo Nordisk | Nov 7, 2014 | 362 |
| NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Mar 2014 | 40 |
| NCT01773798Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2013 | 33 |
| NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more | 3 | Completed | Novo Nordisk | Jan 9, 2014 | 274 |
| NCT01704417Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2013 | 40 |
| NCT01680341Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Aug 22, 2013 | 272 |
| NCT01676116Diabetes Mellitus · United States, Australia, France and more | 3 | Completed | Novo Nordisk | Mar 11, 2014 | 438 |
| NCT01664247Diabetes Mellitus · United States, Canada, France and more | 3 | Completed | Novo Nordisk | Dec 31, 2013 | 346 |
| NCT01618162Diabetes Mellitus · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 23, 2013 | 435 |
| NCT01623375Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2012 | 18 |
| NCT01590836Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2012 | 22 |
| NCT01570751Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 2014 | 145 |
| NCT01569841Diabetes Mellitus · United States | 3 | Completed | Novo Nordisk | Nov 2012 | 24 |
| NCT01513590Diabetes Mellitus · Algeria, Bulgaria, Croatia and more | 3 | Completed | Novo Nordisk | Nov 19, 2012 | 394 |
| NCT01513473Diabetes Mellitus · United States, Bulgaria, Finland and more | 3 | Completed | Novo Nordisk | Jul 30, 2013 | 350 |
| NCT01467414Diabetes Mellitus · Germany | 1 | Terminated | Novo Nordisk | Dec 2011 | 1 |
| NCT01455142Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Jan 2012 | 32 |
| NCT01437592Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Nov 22, 2011 | 24 |
| NCT01392573Diabetes Mellitus · United States, Bulgaria, Denmark and more | 3 | Completed | Novo Nordisk | Oct 1, 2012 | 413 |
| NCT01388361Diabetes Mellitus · United States, Austria, Belgium and more | 3 | Completed | Novo Nordisk | Jul 2012 | 413 |
| NCT01365507Diabetes Mellitus · United States, Korea, Republic of, Malaysia and more | 3 | Completed | Novo Nordisk | Apr 2012 | 276 |
How it is read
Names in the registry
- “insulin degludec”, 73 entries
- “insulin degludec/insulin aspart”, 35 entries
- “insulin degludec/liraglutide”, 17 entries
- “Insulin degludec”, 4 entries
- “Insulin degludec/liraglutide”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 58 studies
- Diabetes Mellitus, Type 1, 31 studies
- Diabetes Mellitus, 16 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.